You are here » Home » Companies » Company Overview » Eiko Lifesciences Ltd

Eiko Lifesciences Ltd.

BSE: 540204 Sector: Industrials
NSE: N.A. ISIN Code: INE666Q01016
BSE 00:00 | 08 Dec 43.00 -0.35
(-0.81%)
OPEN

44.90

HIGH

45.25

LOW

42.20

NSE 05:30 | 01 Jan Eiko Lifesciences Ltd
OPEN 44.90
PREVIOUS CLOSE 43.35
VOLUME 31856
52-Week high 79.85
52-Week low 35.25
P/E 113.16
Mkt Cap.(Rs cr) 36
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 44.90
CLOSE 43.35
VOLUME 31856
52-Week high 79.85
52-Week low 35.25
P/E 113.16
Mkt Cap.(Rs cr) 36
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Eiko Lifesciences Ltd. (EIKOLIFESCIENCE) - Chairman Speech

Company chairman speech

Dear Shareholders

This was yet another year of exciting innovations converting challenges intoopportunities and maintaining focus on operational efficiencies. I am happy to share withyou that despite ongoing COVID-19 pandemic your company has performed well during theyear 2021-22.

Our performance for the year gone by demonstrates our ability to adapt to change ourcommitment and responsibility towards each and every stakeholder. Amidst trying times wedelivered robust results even when the economy witnessed a massive slowdown.

Eiko Lifesciences Limited continued on its journey of sustained growth during theFinancial Year 2021-22. Total Revenues grew by 111.93% from 1199.06 Lakh during 2020-21to 2541.19 Lakh during 2021-22. Profit After Tax (PAT) improved by 14.88 % from 61.43Lakh during 2020-21 to 70.57 Lakh during 2021-22.

The opportunity for growth in the chemical industry is significant as many chemicalunits in China have shut down because of rising environmental concerns. The facilities atEiko can fill this vacuum to meet global requirements. We are bolstering our R&Dinvestments to introduce new products. Our Research & Development (R&D) teamcontinues to develop new products at a healthy pace.

We have completed the development of new molecules for Agrochemical IntermediatesPolymer Science and Pharma segment. Eiko has successfully developed these molecules andhave also launched the same during the second quarter and looking forward for substantialincremental business opportunities in the future. Our Environment Health and Safety teamcontinued its excellent work. Our safety record was excellent. We had no lost timeinjuries.

Finally I would like to express my sincere appreciation to all our employees for theircontribution towards the performance of the Company. I also appreciate the supportreceived from our customers suppliers various Government departments and gratefullyacknowledge the continuous support of all our Shareholders.

Yours sincerely
Laxmikant Kabra
Chairman
Eiko LifeSciences Limited

.